
    
      The purpose of this study is to evaluate efficacy and safety of TG-2349 in combination with
      DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I infected patients.
      Approximately 360 subjects will be enrolled in this study and divided into 2 groups:

      Group 1: Chronic hepatics C virus (HCV) genotype 1 infected, non-cirrhotic subjects.

      Group 2: Chronic hepatics C virus (HCV) genotype 1 infected, cirrhotic subjects.
    
  